Sei Investments invested in 3.89M shares or 0.34% of the stock.
Argent Capital Management Llc decreased its stake in Boston Scientific Corporation (BSX) by 32.57% based on its latest 2017Q4 regulatory filing with the SEC.
Several other institutional investors have also recently bought and sold shares of BSX. The brokerage now has a strong-buy rating on the medical equipment provider's stock. Granite Springs Asset Management LLC now owns 33,450 shares of the medical equipment provider's stock worth $914,000 after buying an additional 2,500 shares during the period. National Pension Service lifted its holdings in shares of Boston Scientific by 2.7% in the 4th quarter. Bank of Montreal Can now owns 2,767,978 shares of the medical equipment provider's stock worth $68,618,000 after purchasing an additional 727,508 shares during the last quarter. Arrowstreet Capital Limited Partnership now owns 7,149,847 shares of the medical equipment provider's stock valued at $177,245,000 after acquiring an additional 5,633,721 shares in the last quarter. Boston Scientific Corporation (BSX) is intriguing when broken down to its core data.
BSX has flown up as the subject of gossips for a number of analysts. ValuEngine raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 2nd. Price Target plays a critical role when it comes to the analysis of a Stock. TheStreet cut Boston Scientific from a "b" rating to a "c" rating in a research note on Monday, March 5th. Boston Scientific Corporation was covered by a number of analysts recently, 13 rated the stock as Buy, 6 rated Outperform, 5 rated Hold, 0 gave an Underperform and 0 rated sell. Finally, Canaccord Genuity reaffirmed a "buy" rating and set a $36.00 target price on shares of Boston Scientific in a research note on Wednesday, April 25th.
Analysts mean recommendation for the stock is 2.40, (where 1 is Strong Buy and 5 is Strong Sell). Investors can maximize their rates of return by buying and selling stocks when they are trading below and above their price targets, respectively.
In other Boston Scientific news, SVP David A. Pierce sold 16,286 shares of the business's stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $30.06, for a total value of $225,450.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. For example, if a stock's beta is 1.2, it's theoretically 20% more volatile than the market. The shares were sold at an average price of $27.54, for a total transaction of $124,150.32. The disclosure for this sale can be found here. The stock price mounted 14.06% in three months and soared 4.44% for the last six months trading period.
NYSE BSX opened at $29.94 on Monday. Boston Scientific has a 52 week low of $28.49 and a 52 week high of $30.35. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.59 and a current ratio of 0.82. BSX stock is now showing negative return of -0.27% throughout last week and witnessed bullish return of 5.48% in one month period.
Boston Scientific Corporation shares increased 1.42 percent over the past week and rose 6.16 percent over the previous month. The medical equipment provider reported $0.33 EPS for the quarter, topping analysts' consensus estimates of $0.32 by $0.01. The firm's revenue was up 10.1% on a year-over-year basis. research analysts predict that Boston Scientific will post 1.39 EPS for the current fiscal year. RBC Capital Markets maintained Boston Scientific Corporation (NYSE:BSX) on Thursday, February 1 with "Buy" rating.
20 analysts on average are expecting the company to report revenue of $2.47 Billion for the current quarter. The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock.
Boston Scientific Corporation (BSX) is an interesting player in the Healthcare space, with a focus on Medical Appliances & Equipment. It operates through three divisions: Cardiovascular, Rhythm Management, and MedSurg.The P/E ratio is 396.25. The firm offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; other coronary therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.